See more : VIGO System S.A. (VGO.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Anika Therapeutics, Inc. (ANIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anika Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- KRM22 Plc (KRMCF) Income Statement Analysis – Financial Results
- Veeva Systems Inc. (VEEV) Income Statement Analysis – Financial Results
- Playground Ventures Inc. (SMPBF) Income Statement Analysis – Financial Results
- Willy-Food Investments Ltd (WLFD.TA) Income Statement Analysis – Financial Results
- The National Company for Glass Industries (2150.SR) Income Statement Analysis – Financial Results
Anika Therapeutics, Inc. (ANIK)
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M | 113.42M | 103.38M | 93.00M | 105.59M | 75.08M | 71.36M | 64.78M | 55.56M | 40.14M | 35.78M | 30.83M | 26.84M | 29.84M | 26.47M | 15.40M | 13.19M | 11.31M | 16.34M | 13.50M | 13.90M | 12.00M | 1.20M | 3.40M | 4.70M | 2.20M |
| Cost of Revenue | 63.57M | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M | 27.36M | 24.03M | 21.05M | 20.93M | 22.77M | 28.99M | 26.78M | 23.83M | 13.67M | 13.19M | 11.88M | 11.12M | 11.14M | 9.95M | 8.01M | 8.11M | 8.23M | 8.67M | 5.30M | 5.20M | 4.40M | 700.00K | 2.80M | 3.70M | 1.90M |
| Gross Profit | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M | 86.06M | 79.35M | 71.95M | 84.66M | 52.32M | 42.37M | 37.99M | 31.73M | 26.47M | 22.59M | 18.95M | 15.72M | 18.69M | 16.52M | 7.40M | 5.08M | 3.08M | 7.66M | 8.20M | 8.70M | 7.60M | 500.00K | 600.00K | 1.00M | 300.00K |
| Gross Profit Ratio | 61.85% | 59.89% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% | 63.14% | 61.46% | 58.58% | 62.65% | 62.41% | 48.03% | 38.51% | 27.26% | 46.91% | 60.74% | 62.59% | 63.33% | 41.67% | 17.65% | 21.28% | 13.64% |
| Research & Development | 32.69M | 28.18M | 27.33M | 23.43M | 16.67M | 18.19M | 18.79M | 10.73M | 8.99M | 8.14M | 7.06M | 5.39M | 6.17M | 6.87M | 8.18M | 7.40M | 4.36M | 3.62M | 4.73M | 4.09M | 2.60M | 3.93M | 4.28M | 3.26M | 4.20M | 2.00M | 2.00M | 0.00 | 1.30M | 1.50M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 0.00 | 900.00K | 700.00K | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.85M | 84.79M | 74.10M | 60.06M | 34.95M | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 2.60M | 900.00K | 700.00K | 1.90M |
| Other Expenses | 62.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54B | 0.00 | 0.00 | 2.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| Operating Expenses | 191.48M | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M | 40.33M | 28.75M | 23.81M | 23.22M | 20.00M | 20.12M | 24.03M | 24.19M | 18.73M | 18.36M | 12.36M | 10.30M | 10.14M | 10.13M | 6.80M | 8.35M | 10.49M | 8.65M | 8.30M | 5.50M | 4.40M | 3.20M | 2.50M | 2.40M | 2.20M |
| Cost & Expenses | 254.30M | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M | 67.69M | 52.77M | 44.87M | 44.15M | 42.76M | 49.11M | 50.81M | 48.02M | 32.40M | 31.55M | 24.24M | 21.41M | 21.28M | 20.08M | 14.81M | 16.46M | 18.72M | 17.32M | 13.60M | 10.70M | 8.80M | 3.90M | 5.30M | 6.10M | 4.10M |
| Interest Income | 0.00 | 654.00K | 188.00K | 498.00K | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.19K | 5.26M | 182.39K | 194.62K | 4.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.22M | 16.35M | 15.99M | 15.00M | 7.17M | 5.91M | 4.29M | 3.73M | 3.78M | 4.71M | 4.77M | 4.53M | 4.00M | 3.32M | 1.29M | 1.43M | 818.73K | 384.06K | 459.00K | 710.00K | 1.01M | 1.10M | 1.23M | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| EBITDA | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | 27.66M | 50.02M | 54.34M | 51.91M | 61.45M | 32.03M | 26.78M | 17.97M | 10.86M | 11.18M | 5.66M | 7.41M | 5.81M | 9.01M | 14.53M | 1.60M | -2.18M | -6.18M | 214.38K | 1.10M | 3.37M | 3.50M | -2.10M | -1.60M | -1.20M | -1.60M |
| EBITDA Ratio | -6.74% | -12.42% | -26.78% | -0.47% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 42.66% | 34.74% | 27.74% | 19.54% | 27.87% | 15.82% | 24.02% | 21.65% | 30.20% | 26.82% | 10.39% | -16.53% | -54.61% | 1.31% | 5.93% | 19.42% | 26.67% | -183.33% | -47.06% | -27.66% | -72.73% |
| Operating Income | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M | 45.73M | 50.61M | 48.13M | 61.45M | 32.61M | 19.72M | 13.97M | 7.54M | 5.59M | 4.23M | 6.59M | 5.43M | 8.55M | 6.39M | 595.00K | -3.27M | -7.41M | -983.37K | -100.00K | 3.20M | 3.20M | -2.70M | -1.90M | -1.40M | -1.90M |
| Operating Income Ratio | -52.58% | -12.42% | -12.50% | -11.09% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% | 11.81% | 21.37% | 20.22% | 28.66% | 24.14% | 3.86% | -24.83% | -65.51% | -6.02% | -0.74% | 23.02% | 26.67% | -225.00% | -55.88% | -29.79% | -86.36% |
| Total Other Income/Expenses | 2.31M | 654.00K | -188.00K | -302.00K | 1.87M | 1.46M | 473.00K | 263.00K | 120.00K | 58.14K | -127.00K | -187.78K | -182.39K | -194.62K | -2.23M | 498.51K | 2.10M | 2.10M | 1.24M | 388.71K | 144.00K | 239.00K | 662.19K | 1.17M | 1.38M | 700.00K | 200.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -85.33M | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M | 46.20M | 50.87M | 48.25M | 61.51M | 32.48M | 19.53M | 13.79M | 7.34M | 5.51M | 4.73M | 8.69M | 7.53M | 9.79M | 6.78M | 739.00K | -3.03M | -6.75M | 189.49K | -100.00K | 4.40M | 3.40M | -2.60M | 0.00 | -1.30M | -1.90M |
| Income Before Tax Ratio | -51.20% | -12.00% | 1.64% | -21.94% | 31.52% | 21.99% | 40.74% | 49.21% | 51.89% | 58.25% | 43.26% | 27.37% | 21.28% | 13.22% | 13.73% | 13.21% | 28.18% | 28.05% | 32.82% | 25.61% | 4.80% | -23.02% | -59.66% | 1.16% | -0.74% | 31.65% | 28.33% | -216.67% | 0.00% | -27.66% | -86.36% |
| Income Tax Expense | -2.66M | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M | 14.39M | 18.32M | 17.50M | 23.19M | 11.91M | 7.77M | 5.32M | 3.03M | 1.82M | 1.10M | 2.65M | 2.92M | 3.90M | -4.41M | -88.00K | 5.00K | 9.08K | 15.94K | 2.20M | 100.00K | 100.00K | -100.00K | 100.00K | -100.00K | -300.00K |
| Net Income | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M | 31.82M | 32.55M | 30.76M | 38.32M | 20.57M | 11.76M | 8.47M | 4.32M | 3.69M | 3.63M | 6.04M | 4.60M | 5.89M | 11.19M | 827.00K | -3.04M | -6.76M | 173.55K | -2.50M | 4.30M | 3.30M | -2.70M | -2.00M | -1.40M | -1.60M |
| Net Income Ratio | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% | 10.14% | 19.58% | 17.15% | 19.75% | 42.28% | 5.37% | -23.05% | -59.74% | 1.06% | -18.52% | 30.94% | 27.50% | -225.00% | -58.82% | -29.79% | -72.73% |
| EPS | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 | 0.34 | 0.32 | 0.32 | 0.55 | 0.43 | 0.57 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.26 | 0.38 | 0.60 | -0.56 | -0.61 | -0.45 | -0.51 |
| EPS Diluted | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 | 0.32 | 0.53 | 0.41 | 0.52 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.24 | 0.34 | 0.44 | -0.56 | -0.61 | -0.45 | -0.51 |
| Weighted Avg Shares Out | 14.66M | 14.56M | 14.40M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M | 12.62M | 11.39M | 11.31M | 11.06M | 10.64M | 10.41M | 11.42M | 9.95M | 9.93M | 9.93M | 9.87M | 9.74M | 9.89M | 5.00M | 4.82M | 3.28M | 3.11M | 3.14M |
| Weighted Avg Shares Out (Dil) | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M | 13.65M | 11.56M | 11.46M | 11.45M | 11.16M | 11.43M | 11.42M | 10.85M | 9.93M | 9.93M | 10.04M | 10.22M | 11.01M | 7.50M | 4.82M | 3.28M | 3.11M | 3.14M |
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial...
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.
Anika Reports Second Quarter 2024 Financial Results
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand
Anika to Participate in the Sidoti Virtual Investor Conference
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika...
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500...
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of...
Anika Enters into Cooperation Agreement with Caligan Partners
Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program
Source: https://incomestatements.info
Category: Stock Reports